India Glycols Ltd

India Glycols Q1 FY27 Results & Future Ambitions 📈

- Q1 FY27 Net Revenue: INR1,130 crores (up 9% YoY).

- Q1 FY27 EBITDA: INR170 crores (up 13% YoY).

- Q1 FY27 PAT: Up 32% YoY.

- IGL Spirits Segment (including Bio-Fuel) Q1 Revenue: INR694 crores with EBITDA of INR120 crores (margin 17.3%).

- Spirits Business Revenue: INR361 crores (up 5.3% YoY).

- Chemicals Business Revenue: INR345 crores (up 24% YoY) with EBITDA of INR40 crores (margin 11.6%).

- Ennature Bio Pharma Revenue: INR90 crores (up 53% YoY) with EBITDA of INR10 crores (margin 11.1%, up ~100% YoY).

- Bio-Fuel Segment Revenue: INR323 crores with EBIT of INR27 crores (margin 8.4%).

- Management Targets for IGL Spirits: Exceed INR500 crores EBITDA in FY27; aspire to exceed INR1,000 crores EBITDA in 4-5 years.

- Management Aspiration for Chemicals: Reach ~INR2,500 crores revenue and ~INR400 crores EBITDA in 4-5 years.

- Management Aspiration for Ennature Bio Pharma: Achieve EBITDA of INR130-150 crores in 4-5 years.

- Finance Costs: Declined to INR25 crores in Q1 FY27 from INR45 crores in Q1 FY26 due to debt reduction.

- Geopolitical events noted as creating both headwinds (supply chain, freight costs) and tailwinds (improved competitiveness of bio-based EO).